- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04633681
Impact of Sweeteners on Behaviour, Physiology & Health (SWEET-WP2-P2)
Acute and Repeated Impact of Sweeteners and Sweetness Enhancers on Food Behaviour, Physiology & Health (SWEET Work Package 2 Phase 2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This protocol has the overall objective to evaluate the acute (short-term, 1 day) and repeated (medium-term, 2 week) effects of combinations of sweeteners and sweetness enhancers (S&SEs) on metabolic, sensory, neuro-behavioural and microbiota-mediated processes involved in satiety, consumer preference and health, and to explore mechanistic processes, genetic background, safety issues and consumer perspectives.
There are 5 products being tested in 3 different formulations (sucrose-sweetened control vs 2 reformulated with S&SE). Each product will be tested at 2 intervention sites in double-blind cross-over trials with 48 subjects (24 per site) tested per product. Therefore a total of 240 subjects will take part across the 5 intervention sites (Navarra, Leeds, Liverpool, Copenhagen, Lyon).
Using identical procedures each trial will consist of 2 Clinical Investigation Days (CIDs) scheduled 12 days apart for each of the 3 product formulations. A 2-week wash-out period will be given between formulations.
The total duration of WP2 Phase 2 is 12 months, including a 5-month duration for each cross-over trial.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Graham S Finlayson, PhD
- Phone Number: +441133437601
- Email: g.s.finlayson@leeds.ac.uk
Study Contact Backup
- Name: Catherine H Gibbons, PhD
- Phone Number: +441133432947
- Email: c.gibbons@leeds.ac.uk
Study Locations
-
-
-
Copenhagen, Denmark
- Not yet recruiting
- University of Copenhagen
-
Contact:
- Anne Raben, PhD
-
-
-
-
-
Lyon, France
- Recruiting
- CRNH-RA
-
Contact:
- Nazare Julie-Anne, PhD
-
-
-
-
-
Pamplona, Spain, 31009
- Not yet recruiting
- University of Navarra
-
Contact:
- J. Alfredo Martinez, PhD
-
-
-
-
-
Liverpool, United Kingdom
- Not yet recruiting
- University of Liverpool
-
Contact:
- Charlotte Hardman, PhD
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom, LS2 9JT
- Recruiting
- University of Leeds
-
Contact:
- Graham Finlayson, PhD
- Phone Number: 01133437601
- Email: g.s.finlayson@leeds.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI: 25 to 35 kg/m2
- Use of contraceptive methods or not planning to become pregnant for the duration of the study (women only)
- Regular consumption of sugar-containing foods and willing to consume sugar and artificially-sweetened food products.
- Liking of the intervention foods defined by a response of Yes for the product during the pre-screening interview and a score of 40% or above on the Liking Visual Analogue Scale for the sucrose-sweetened control product.
- Able to participate on the Clinical Investigation Days during normal working hours.
- Healthy as determined from the self-reported medical history or when a clinical condition exists, when this is considered to be irrelevant (i.e. not influencing study outcomes) for the study by the study medical doctor.
- Consuming breakfast regularly (at least 5 days per week).
- Able to understand and be willing to sign the informed consent form, and to follow all the study procedures and requirements.
- Capacity to store at-home intervention quantity of intervention product
Exclusion Criteria:
- Blood donation < 3 month prior to study or for full duration of the study.
- Food allergy, intolerance, restriction or avoidance of any of the study foods (e.g. veganism) or history of anaphylactic reaction to any food.
- Likelihood for disordered eating defined as a score ≥20 on the Eating Attitudes Test.
- Currently dieting to lose weight.
- Having lost or gained >4.5 kg in the last 3 months.
- Smoking or having quit <3 months prior to study.
- Habitually consuming >14 units/week of alcohol in women or >21 units/week in men in the last 3 months.
- Performing >10 h of intense physical activity per week in the last 3 months.
- Night or late shift work (ending later than 11 pm on a permanent basis). Rotational shift work allowed if can attend on days that do not follow a late/night shift.
- Self-reported use of drugs of abuse within the previous 12 months.
- Pregnancy, lactation (women only)
- Persons who do not have access to either (mobile) phone or internet (this is necessary when being contacted by the study personnel during the study).
- Insufficient communication in the national language.
- Proven or suspected inability, physically or mentally, to comply with the procedures required by the study protocol as evaluated by the daily study manager, site-PI, PI or clinical responsible. This includes volunteers for which insufficient collaboration may be foreseen.
- Subject's general condition contraindicates continuing in the study as evaluated by the daily study manager, site-PI, PI or responsible clinician.
- Simultaneous participation in other relevant clinical intervention studies.
- Previous university or college training related to eating behaviour research.
- Self-reported eating disorders.
- Diagnosed anaemia.
- Diagnosed diabetes mellitus.
- Abnormal G.I. function or structure such as malformation, angiodysplasia, active peptic ulcer.
- Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption.
- History of G.I. surgery with permanent effect (i.e. surgical treatment of obesity).
- Medical history of Cardiovascular Disease (e.g. current angina; myocardial infarction or stroke within the past 6 months; heart failure; symptomatic peripheral vascular disease).
- Significant liver disease, e.g. cirrhosis (fatty liver disease allowed).
- Malignancy which is currently active or in remission for less than five years after last treatment (local basal and squamous cell skin cancer allowed).
- Thyroid diseases, except those on Levothyroxine treatment of hypothyroidism if the person has been on a stable dose for at least 3 months.
- Psychiatric illness (e.g. major depression, bipolar disorders).
- Use currently or within the previous 3 months of prescription or over the counter medication that has the potential of affecting appetite, satiety or body weight incl. food supplements. Except: low dose antidepressants if they, in the judgement of the daily study manager, site-PI, PI or clinical responsible, do not affect weight or following the study protocol. Levothyroxine for treatment of hypothyroidism is allowed if the person has been on a stable dose for at least 3 months.
- Cholesterol lowering medication, if the dose has changed during the last 3 months (i.e. the medication is allowed if the participant has been on a stable dose for at least 3 months).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cake matrix
3 phases of 2-week daily consumption of cake product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
|
Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
|
Experimental: Biscuit matrix
3 phases of 2-week daily consumption of biscuit product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
|
Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
|
Experimental: Yoghurt matrix
3 phases of 2-week daily consumption of yoghurt product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
|
Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
|
Experimental: Chocolate matrix
3 phases of 2-week daily consumption of chocolate product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
|
Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
|
Experimental: Cereal matrix
3 phases of 2-week daily consumption of cereal product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
|
Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
|
Experimental: Universal Eating Monitor study
A sub-group of the yoghurt matrix will be selected for assessment of eating rate and microstructure of feeding using Universal Eating Monitors.
|
Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
|
Experimental: fMRI study
A sub-group of the chocolate matrix will be selected for assessment of neural activation to images of food using fMRI.
|
Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite Appetite Sensations Incremental Area Under the Curve
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve (iAUC) for composite appetite sensations in response to each product. During each of the Clinical Investigation Days iAUC composite appetite will be measured 180 minutes post intake. The following sensations of appetite will be used in the composite measure:
Minimum value 0 Maximum value 100 Higher scores mean worse outcome |
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Leeds Food Preference Questionnaire (LFPQ) Explicit Liking
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Change in explicit liking for foods at 15 min post intake Minimum value -100 Maximum value 100 Higher scores mean worse outcome
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Leeds Food Preference Questionnaire (LFPQ) Implicit Wanting
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Change in implicit wanting for foods at 15 min post intake Minimum value -100 Maximum value 100 Higher scores mean worse outcome
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Leeds Food Preference Questionnaire (LFPQ) Relative preference
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Change in relative preference for foods at 15 min post intake Minimum value -48 Maximum value 48 Higher scores mean worse outcome
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Leeds Food Preference Questionnaire (LFPQ) Explicit wanting
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Change in explicit wanting for foods at 15 min post intake Minimum value -100 Maximum value 100 Higher scores mean worse outcome
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Control of Eating Questionnaire (CoEQ): Craving Control
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Craving Control examined in a fasted state.
Minimum value 0 Maximum value 100 Higher scores mean better outcome
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Control of Eating Questionnaire (CoEQ): Craving for Sweet
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Craving for Sweet examined in a fasted state.
Minimum value 0 Maximum value 100 Higher scores mean worse outcome
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Control of Eating Questionnaire (CoEQ): Craving for Savoury
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Craving for Savoury examined in a fasted state.
Minimum value 0 Maximum value 100 Higher scores mean worse outcome
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Control of Eating Questionnaire (CoEQ): Positive Mood
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Positive Mood examined in a fasted state.
Minimum value 0 Maximum value 100 Higher scores mean better outcome
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Blood Glucose Incremental Area Under the Curve
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve for blood glucose concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Blood Insulin Incremental Area Under the Curve
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve for blood insulin concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Cephalic and intestinal satiety biomarkers: Glucagon-like peptide-1 (GLP-1)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve for blood GLP-1 concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Cephalic and intestinal satiety biomarkers: Ghrelin
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve for blood Ghrelin concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body composition: fat mass (kg)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Anthropometry marker fat mass
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Body composition: fat-free mass (kg)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Anthropometry marker fat-free mass
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Body weight (kg)
Time Frame: Fasting during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Anthropometry marker body weight
|
Fasting during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Standing height (cm)
Time Frame: Measured in a fasting state during screening day only
|
Anthropometry marker standing height
|
Measured in a fasting state during screening day only
|
Waist circumference (cm)
Time Frame: Fasting during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Anthropometry marker waist circumference
|
Fasting during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Body composition, body weight, height, waist and hip circumference
Time Frame: Fasting during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Anthropometry marker hip circumference
|
Fasting during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Sweet taste receptor polymorphism prevalence
Time Frame: Clinical Investigation Day 1 only in a fasted state
|
Blood DNA analysis for sweet taste receptor polymorphism prevalence
|
Clinical Investigation Day 1 only in a fasted state
|
Consumers' Perspectives Questionnaire on sweeteners
Time Frame: Fasted state on screening day only (Day 0)
|
Psychological health drivers (perceptions) of sweetener consumption
|
Fasted state on screening day only (Day 0)
|
Gut microbiota profile (diversity and ratio)
Time Frame: Collected the day before each Clinical Investigation Day for the yoghurt food matrix.
|
Gut microbiota measured from fecal samples during clinical investigation days in yoghurt matrix only
|
Collected the day before each Clinical Investigation Day for the yoghurt food matrix.
|
Brain activity (fMRI)
Time Frame: Clinical Investigation Day 1 and Clinical Investigation Day 6 immediately before and immediately after consumption of the chocolate food matrix.
|
Neural activation to chocolate matrix only
|
Clinical Investigation Day 1 and Clinical Investigation Day 6 immediately before and immediately after consumption of the chocolate food matrix.
|
Meal eating behaviour and microstructure: Eating rate
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Eating rate using the Universal Eating Monitor in yoghurt matrix only
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Meal eating behaviour and microstructure: Bite count
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Bite count using the Universal Eating Monitor in yoghurt matrix only
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Urinary S&SEs biomarkers
Time Frame: Collected the day before each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Biomarkers of S&SE quality measured from urine samples
|
Collected the day before each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Eating behaviour traits: Three factor eating questionnaire Restraint subscale
Time Frame: Fasted state on screening day only (Day 0)
|
Restraint eating behaviour trait measured by the Three Factor Eating Questionnaire. Minimum value 0 Maximum value 21 Higher scores mean worse outcome |
Fasted state on screening day only (Day 0)
|
Eating behaviour traits: Three factor eating questionnaire Hunger subscale
Time Frame: Fasted state on screening day only (Day 0)
|
Hunger eating behaviour trait measured by the Three Factor Eating Questionnaire. Minimum value 0 Maximum value 14 Higher scores mean worse outcome |
Fasted state on screening day only (Day 0)
|
Eating behaviour traits: Three factor eating questionnaire Disinhibition subscale
Time Frame: Fasted state on screening day only (Day 0)
|
Disinhibition eating behaviour trait measured by the Three Factor Eating Questionnaire. Minimum value 0 Maximum value 16 Higher scores mean worse outcome |
Fasted state on screening day only (Day 0)
|
Eating behaviour traits: Binge Eating Scale
Time Frame: Fasted state on screening day only (Day 0)
|
Binge Eating measured by the Binge Eating Scale Minimum value 0 Maximum value 46 Higher scores mean worse outcome |
Fasted state on screening day only (Day 0)
|
Habitual intake of sweet foods
Time Frame: Fasted state on screening day only (Day 0)
|
Short sugar Food Frequency Questionnaire (short sFFQ)
|
Fasted state on screening day only (Day 0)
|
Perception and evaluation of the clinical trial
Time Frame: Clinical Investigation Day 6
|
End of study survey
|
Clinical Investigation Day 6
|
24-h Dietary recall: Self-reported energy intake
Time Frame: Next day after each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Interview to know what the volunteers ate during the 24h following each probe day
|
Next day after each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
24-h Dietary recall: Energy compensation after intake of intervention products
Time Frame: Next day after each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Interview to know what the volunteers ate during the 24h following each probe day accounting for the energy contained in the intervention food products
|
Next day after each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Expected satiety
Time Frame: Immediately before consuming food product during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Single-item Visual Analogue Scale assessing expected satiety from the intervention food products Minimum value 0 Maximum value 100 Higher scores mean better outcome
|
Immediately before consuming food product during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Sensory-specific satiety
Time Frame: Immediately before and immediately after consuming food product during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Single-item Visual Analogue Scale assessing sensory-specific satiety from the intervention food products Minimum value 0 Maximum value 100 Higher scores mean better outcome
|
Immediately before and immediately after consuming food product during each Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Thirst Incremental Area Under the Curve
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve (iAUC) for thirst in response to each product. During each of the Clinical Investigation Days iAUC thirst will be measured 180 minutes post intake using visual analogue scale. Minimum value 0 Maximum value 100 Higher scores mean worse outcome |
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Nausea Incremental Area Under the Curve
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve (iAUC) for nausea in response to each product. During each of the Clinical Investigation Days iAUC nausea will be measured 180 minutes post intake using visual analogue scale. Minimum value 0 Maximum value 100 Higher scores mean a worse outcome. |
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Bloating Incremental Area Under the Curve
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve (iAUC) for bloating in response to each product. During each of the Clinical Investigation Days iAUC bloating will be measured 180 minutes post intake using visual analogue scale. Minimum value 0 Maximum value 100 Higher scores mean worse outcome |
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Cephalic and intestinal satiety biomarkers: Pancreatic polypeptide (PP)
Time Frame: During each of the probe day visits blood pancreatic polypeptide (PP) will be measured at baseline, and 5, 10, 30 minutes after consuming the product. Each visit will be separated by 12 days of daily consumption of the product.
|
Incremental area under the curve for blood PP concentrations in response to each product (120 min post intake).
|
During each of the probe day visits blood pancreatic polypeptide (PP) will be measured at baseline, and 5, 10, 30 minutes after consuming the product. Each visit will be separated by 12 days of daily consumption of the product.
|
Lipaemia: triglycerides
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve for blood triglyceride concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Lipaemia: Cholesterol (total)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve for blood cholesterol (total) concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Lipaemia: Cholesterol (HDL)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve for blood cholesterol (HDL) concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Lipaemia: Cholesterol (LDL)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Incremental area under the curve for blood cholesterol (LDL) concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Liver function: Alanine aminotransferase (ALT)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Mean of liver function marker (ALT) concentrations in response to each product (120 min post intake).
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Liver function: Aspartate aminotransferase (AST)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Mean of liver function marker (AST) concentrations in response to each product 120 min post intake.
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Liver function: Gamma-Glutamyl Transpeptidase (GGT)
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Mean of liver function marker (GGT) concentrations in response to each product 120 min post intake.
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Liver function: Fatty Liver index
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Mean of liver function marker (FL index) concentrations in response to each product 120 min post intake.
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Liver function: Triglyceride index
Time Frame: Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
Mean of liver function marker (TyG index) concentrations in response to each product 120 min post intake.
|
Clinical Investigation Day 1, 2, 3, 4, 5, 6
|
HbA1c
Time Frame: Measured in a fasting state during Clinical Investigation Day 1 and 6 only
|
Fasting HbA1c blood concentrations
|
Measured in a fasting state during Clinical Investigation Day 1 and 6 only
|
24 hour Gastrointestinal side effects
Time Frame: Up to 24 hours after each Clinical Investigation Day and from Clinical Investigation Day 1, 2, 3, 4, 5, 6 during the 3 at home intervention periods up to 12 days
|
GI side effects reported in a booklet to know if the volunteers experience side effects during the intervention periods
|
Up to 24 hours after each Clinical Investigation Day and from Clinical Investigation Day 1, 2, 3, 4, 5, 6 during the 3 at home intervention periods up to 12 days
|
Adverse events
Time Frame: Up to 24 hours after each Clinical Investigation Day and from Clinical Investigation Day 1, 2, 3, 4, 5, 6 during the 3 at home intervention periods up to 12 days
|
Adverse event reported in a booklet to know if the volunteers experience side effects during the intervention periods
|
Up to 24 hours after each Clinical Investigation Day and from Clinical Investigation Day 1, 2, 3, 4, 5, 6 during the 3 at home intervention periods up to 12 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 774293-WP2-P2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eating Behavior
-
McGill UniversityCompleted
-
McGill UniversityCompleted
-
Pennington Biomedical Research CenterWeight Watchers InternationalNot yet recruitingEating Behavior
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
McGill UniversityMcMaster University; University of Sydney; Institut National du Sport du QuebecRecruiting
-
University of MichiganAmerican Heart AssociationActive, not recruiting
-
Wageningen UniversityCompletedEating BehaviorNetherlands
-
Penn State UniversityJenny Craig, Inc.Withdrawn
-
Stanford UniversityCompleted
Clinical Trials on Sweetener and sweetness enhancer consumption
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)Recruiting
-
Routin SACompletedHealthy VolunteersFrance
-
Sciwind Biosciences APAC CO Pty. Ltd.Hangzhou Sciwind Biosciences Co., Ltd.Not yet recruitingObesity | Type 2 Diabetes MellitusAustralia
-
Virginia Polytechnic Institute and State UniversityRecruitingInsulin Sensitivity | Inflammatory Markers | Continuous Glucose Monitoring | Oral Glucose ToleranceUnited States
-
Virginia Polytechnic Institute and State UniversityNational Institute on Aging (NIA)RecruitingInsulin Sensitivity | Inflammatory Markers | Continuous Glucose Monitoring | Oral Glucose ToleranceUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedGut Microbiota | GLP-1Mexico
-
Purdue UniversityDairy Research InstituteCompletedBlood Glucose | Blood InsulinUnited States
-
Applied Science Private UniversityUnknownAtherosclerosisJordan
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
University of MinnesotaWithdrawnStress Perception | Discretionary Calories | Over All HealthUnited States